Vosaroxin is under clinical development by Denovo Biopharma and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vosaroxin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vosaroxin overview

Vosaroxin (Voreloxin, Qinprezo) is under development for the treatment of untreated acute myelocytic leukemia and myelodysplastic syndrome (MDS) patients. Vosaroxin is a naphthyridine analog of anticancer quinolone derivative or AQD. It is administered as an intravenous infusion. Vosaroxin acts by targeting DNA and topoisomerase II. The drug candidate was also under development for the treatment of advanced small cell lung cancer, advanced non-small cell lung cancer, and platinum-resistant epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.

It was under development for the treatment of glioblastoma multiforme.

Denovo Biopharma overview

Denovo Biopharma, formerly Denovo Biomarkers is a biotechnology company that provides novel biomarker solutions to personalize drug development. The company enables drug developers to design new clinical trials in targeted patient populations and re-evaluates medicines that failed in general patient populations. Its core technology performs genomic biomarker discovery using archived clinical samples. Denovo Biopharma supports its partners throughout the evolution process up to the approval and launch of the drug together with the companion diagnostic test. The company also partners with life science companies and drug developers. It has operations in the US and China. Denovo Biopharma is headquartered in San Diego, California, the US.

For a complete picture of Vosaroxin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.